In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models

In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models

IntroductionThe approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of B cell malignancies has fueled the development of numerous ex vivo cell therapies. However, these cell therapies are complex and costly, and unlike in hematological malignancies, outcomes with most T ce...

Full description

Saved in:
Bibliographic Details
Main Authors: Shannon Argueta, Yuxiao Wang, Hongyun Zhao, Neha Diwanji, Michael Gorgievski, Edward Cochran, Ewa Grudzien-Nogalska, Josephine D’Alessandro, Bruce McCreedy, Thomas Prod’homme, Robert Hofmeister, Jian Ding, Daniel Getts
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
cancer therapy
lipid nanoparticles
myeloid cells
RNA therapeutics
cell therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1501365/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1501365/full

Similar Items